75385-92-1

Upstream product

• 79-37-8 oxalyl dichloride 
• 122-39-4 diphenylamine 
• 17425-91-1 N-(trimethylsilyl)-diphenylamine 

Downstream Products

• 1359823-95-2 N₁,N₁-diphenyl-N₂-o-tolyloxalamide 
• 1359824-02-4 C₁₅H₁₄N₂O₂ 
• 1029033-90-6 N₁-(2-hydroxyphenyl)-N₂,N₂-diphenyloxalamide 
• 1359823-99-6 C₂₀H₁₅N₃O₄ 
• 1359824-01-3 C₁₅H₁₄N₄O₂S 
• 1359824-05-7 C₁₆H₁₆N₂O₂ 
• 1359823-98-5 4-(2-(diphenylamino)-2-oxoacetamido)benzoic acid 
• 1359824-00-2 C₂₀H₁₅ClN₂O₂ 
• 1359823-96-3 N₁,N₁-diphenyl-N₂-p-tolyloxalamide 
• 1359824-04-6 C₂₀H₁₆N₂O₃ 
• 1359823-97-4 N₁,N₁-diphenyl-N₂-(pyrimidin-2-yl)oxalamide 
• 1041193-09-2 N,N-diphenyl-N'-(1-phenyl-ethyl)-oxalamide 
• 105431-72-9 linopirdine 
• 149196-87-2 1,3-Dihydro-3-hydroxy-1-phenyl-3-(4-pyridinylmethyl)-2H-indol-2-one Acetate Ester 

Relevant academic research and scientific papers

One-pot method for preparing 9 - acridine formic acid

The invention discloses a one-pot method for preparing 9 - acridine formic acid. After completion of the reaction, the unreacted oxalyl chloride and the reaction solvent are then distilled 5 - 10 °C off under reduced pressure until the reaction is complet

Design and synthesis of novel diphenyl oxalamide and diphenyl acetamide derivatives as anticonvulsants

A series of novel N1-substituted-N2,N 2-diphenyl oxalamides 3a-l were synthesized in good yield by stirring diphenylcarbamoyl formyl chloride (2) and various substituted aliphatic, alicyclic, aromatic, heterocyclic amines

MALE CONTRACEPTIVE

A compound having formula (I). R1, R2, R3 and R4 are independently H or lower alkyl. R5 is aryl, heteroaryl, cycloalkyl, heterocycloalkyl, aryloxy, heteroaryloxy, cycloalkyloxy, heterocycloalkyloxy, a

Design, synthesis and?in?vivo anticonvulsant screening in?mice of?Novel phenylacetamides

A set of seven novel N-substituted 2-anilinophenylacetamides were designed by pharmacophore generation and using flexible alignment module of MOE software. The novel molecules were synthesized and screened for anticonvulsant activity in Swiss albino mice by MES and ScPTZ induced seizure tests. Test compounds were found to be potent in MES test. Compounds 12 and 14 were found to be more potent with ED50 values 24.0 and 8.0?mg kg-1, respectively, and their activity was comparable to standard drugs (Phenytoin, Carbamazepine). Test compounds did not show significant activity in ScPTZ test. Compounds 12 and 14 also exhibited higher protective indices (20.3 and 87.5, respectively) when assessed for neurotoxicity by rotarod test as compared to the standards.

Processes and polymorphs of diaryl-indolone galr3 antagonists

This invention relates to crystalline forms, as well as an amorphous form of Compound I [1-phenyl-3-[[3-(trifluoromethyl)phenyl]imino]-1H-indol-2-one], the processes for their preparation, compositions containing the same and the therapeutic use of such c

PROCESSES AND POLYMORPHS OF DIARYL-INDOLONE GALR3 ANTAGONISTS

This invention relates to crystalline forms, as well as an amorphous form of Compound I [1-phenyl-3-[[3--(trifluoromethyl)phenyl]imino]-1H-indol-2-one], the processes for their preparation, compositions containing the same and the therapeutic use of such

Structure and Colour of P,P'-Tetra-t-butyl- and P,P'-Tetraphenyl Oxalic Acid Diphosphide and Derivatives

The unexpected violet colour of P,P'-Tetraphenyl-oxalic acid diphosphide (3) stimulated the synthesis of the following derivatives: P,P'-tetra-t-butyl-oxalic acid diphosphide (2).N,P-tetraphenyl-oxalic acid amide phosphide (4) and P,α-triphenyl-glyoxylic